Literature DB >> 16012278

Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence.

Raymond F Anton1, Darlene H Moak, Patricia Latham, L Randolph Waid, Hugh Myrick, Konstantin Voronin, Angelica Thevos, Wei Wang, Robert Woolson.   

Abstract

Although naltrexone has been shown to be effective in the treatment of alcohol dependence, less is known about its efficacy when combined with different behavioral therapies. Previous work has suggested that naltrexone works best when combined with weekly cognitive behavioral therapy (CBT). This study examined the efficacy of naltrexone when combined with CBT or a motivational enhancement therapy involving less patient contact. Outpatient alcoholics (N = 160) were randomly assigned to either naltrexone (50 mg/d) or placebo and either CBT (12 sessions) or motivational enhancement therapy (4 sessions), in a 4-cell design, and treated over a 12-week period. Subjects were evaluated periodically for alcohol consumption, craving, and biologic markers of drinking (carbohydrate-deficient transferrin and gamma-glutamyltransferase). There was high retention and adherence to therapy and medication in the trial with no significant difference across the treatment groups. Naltrexone, independent of therapy assignment, increased the time to first relapse. However, the CBT-naltrexone group did better than the other groups on a variety of outcome measures. Fewer CBT-naltrexone-treated subjects relapsed, and those that did had both fewer, and more time between, subsequent relapses. This randomized controlled trial is consistent with previous reports about the utility of combining naltrexone with CBT. Despite being more efficient to administer, the combination of motivational enhancement therapy and naltrexone is less effective than CBT and naltrexone. Because CBT and naltrexone share common mechanisms of action, such as craving reduction and relapse prevention, these therapies are likely to be well suited to use in combination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012278     DOI: 10.1097/01.jcp.0000172071.81258.04

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  33 in total

1.  Withdrawal from free-choice high-fat high-sugar diet induces craving only in obesity-prone animals.

Authors:  Chris Pickering; Johan Alsiö; Anna-Lena Hulting; Helgi B Schiöth
Journal:  Psychopharmacology (Berl)       Date:  2009-02-11       Impact factor: 4.530

2.  A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.

Authors:  Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler
Journal:  J Consult Clin Psychol       Date:  2012-05-21

3.  The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

Authors:  Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

4.  Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.

Authors:  Ralitza Gueorguieva; Ran Wu; John H Krystal; Dennis Donovan; Stephanie S O'Malley
Journal:  Addict Behav       Date:  2013-02-04       Impact factor: 3.913

Review 5.  Cognitive behavioral therapy for substance use disorders.

Authors:  R Kathryn McHugh; Bridget A Hearon; Michael W Otto
Journal:  Psychiatr Clin North Am       Date:  2010-09

Review 6.  A review of treatment options for co-occurring methamphetamine use disorders and depression.

Authors:  Tracy L Hellem; Kelly J Lundberg; Perry F Renshaw
Journal:  J Addict Nurs       Date:  2015 Jan-Mar       Impact factor: 1.476

7.  Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials.

Authors:  Molly Magill; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

Review 8.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 9.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

10.  Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.

Authors:  Konstantin Voronin; Patrick Randall; Hugh Myrick; Raymond Anton
Journal:  Alcohol Clin Exp Res       Date:  2008-09-08       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.